Aktieanalys

SenzaGen: Expanded testing portfolio - Redeye

{newsItem.title}

Redeye Publicerad: 10 Apr 12:35

Redeye comments on SenzaGen’s expanded testing portfolio, introducing the EpiSensA method, which complements its current GARDskin test. We are positive about the expanded portfolio and see the early orders as a positive signal of market interest.

Länk till analysen i sin helhet: https://www.redeye.se/research/1094278/senzagen-expanded-testing-portfolio?utm_source=finwire&utm_medium=RSS

Nyheter om SenzaGen

Läses av andra just nu

Om aktien SenzaGen

Senaste nytt